prostate cancer stem cells (Celprogen Inc)
Celprogen Inc is a verified supplier 
Celprogen Inc manufactures this product 
93
Structured Review
Celprogen Inc
prostate cancer stem cells
Prostate Cancer Stem Cells, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+cancer+stem+cells/Human+Prostate+Cancer+Stem+Cells/pmc12392137-24-20-52
Average 93 stars, based on 11 article reviews
Prostate Cancer Stem Cells, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+cancer+stem+cells/Human+Prostate+Cancer+Stem+Cells/pmc12392137-24-20-52
Average 93 stars, based on 11 article reviews
prostate cancer stem cells - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
In Vitro:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Animal Model:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Angiogenesis Assay:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Wound Healing Assay:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Migration:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Cell Cycle Assay:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Staining:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target H2O2 Assay:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Glutathione Assay:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Confocal Microscopy:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Flow Cytometry:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Western Blot:Article Title: Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms Article Snippet: Wang et al. (2019), China [ ] , Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cells Identify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy. Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression , Cancer type : Liver Cell lines used : Hep3B Huh7 HepG2 SNU182 SNU398 SNU449 Huh6 SK‐Hep1 PLC/PRF/5 MHCC97H HCCLM3 Animal model : 6‐week‐old male BALB/c nude mice Subcutaneously injected with 5 × 10 6 Huh7 or MHCC97H liver cancer cells into the right posterior flank , CRISPR‐Cas9 genetic screening Clonogenic survival assay SA‐β‐gal staining Western blotting (CDC7, mTOR, apoptosis markers) Caspase‐3/7 apoptosis assay Gene set enrichment analysis Flow cytometry IF RNA sequencing mTOR signaling assays Neutral comet assay Live imaging of mitotic duration Tumor volume measurement in xenografts IHC MRI‐based tumor volume tracking , IC 50 : Not reported Animal model : Mice treated daily via oral gavage for 12–22 days with: ○ XL413 (50–100 mg/kg) to induce tumor senescence ○ AZD8055 (10–20 mg/kg) as mTOR inhibitor ○ Sertraline as a senolytic to selectively kill senescent cells post‐CDC7 inhibition Treatment continued until tumors reached ~2000 mm 3 or symptoms appeared , CDC7 inhibition selectively induced senescence in TP53‐mutant HCC cells, creating a therapeutic vulnerability A drug screen identified sertraline as a senolytic, inducing apoptosis in senescent HCC cells Sertraline acted by suppressing mTOR signaling and preventing feedback activation In vitro, the combination of CDC7 inhibition and sertraline significantly reduced HCC cell viability In vivo, this combination suppressed tumor growth and prolonged survival in xenograft models Sertraline's senolytic activity was comparable to mTOR inhibitors like AZD8055 Supports a “one‐two punch” strategy: CDC7 inhibition induces senescence, sertraline eliminates senescent cells. .. Chinnapaka et al. (2020), United States of America [ ] , To determine whether the TCTP inhibitor sertraline could target Cell Culture:Article Title: Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase Article Snippet: .. Well-characterized Article Title: Increased Chemosensitivity via Targeting Testicular Nuclear Receptor 4 (TR4)-Oct4-Interleukin 1 Receptor Antagonist (IL1Ra) Axis in Prostate Cancer CD133 + Stem/Progenitor Cells to Battle Prostate Cancer Article Snippet: .. The C4-2 human PCa cells and Article Title: Protein kinase C-delta inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo Article Snippet: Breast cancer cell lines MCF7, Hs587T, and MDA231 were purchased from ATCC, and were propagated in 10% fetal bovine serum (Invitrogen, Grand Island, NY); Dulbecco’s Modification of Earle’s Media (Cellgro, Herndon, VA); 2 mM L-Glutamine (Invitrogen); 200 U Penicillin/ml; 200 μg Streptomycin/ml (Invitrogen). .. Human breast cancer stem cells (BCSC: CD133+, CD44+, SSEA3/4+, Oct4+, Alkaline Phosphatase+, Aldehyde Dehydrogenase+, Telomerase+), pancreatic cancer stem cells (PCSC: CD44 + , CD133 + , SSEA3/4 + , Oct4 + , Alkaline Phosphatase + , Aldehyde Dehydrogenase + , Telomerase + , and Nestin + ), and Isolation:Article Title: Peptide-targeted, stimuli-responsive polymersomes for delivering a cancer stemness inhibitor to cancer stem cell microtumors Article Snippet: .. [ 7 ] |